Does the media favor BIOA or DNLI?

In the previous week, BioAge Labs had 6 more articles in the media than Denali Therapeutics. MarketBeat recorded 12 mentions for BioAge Labs and 6 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.01 beat BioAge Labs' score of 0.35 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAge Labs 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Denali Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to RLAY or BIOA?

In the previous week, Relay Therapeutics had 4 more articles in the media than BioAge Labs. MarketBeat recorded 16 mentions for Relay Therapeutics and 12 mentions for BioAge Labs. Relay Therapeutics' average media sentiment score of 0.79 beat BioAge Labs' score of 0.35 indicating that Relay Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 10 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive BioAge Labs 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to ADPT or BIOA?

In the previous week, Adaptive Biotechnologies had 19 more articles in the media than BioAge Labs. MarketBeat recorded 31 mentions for Adaptive Biotechnologies and 12 mentions for BioAge Labs. Adaptive Biotechnologies' average media sentiment score of 0.50 beat BioAge Labs' score of 0.35 indicating that Adaptive Biotechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 9 Very Positive mention(s) 7 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive BioAge Labs 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has stronger valuation & earnings, BIOA or OGN?

Organon & Co. has higher revenue and earnings than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioAge Labs $8.99M 47.42 -$80.61M -$2.40 N/A Organon & Co. $6.13B 0.58 $187M $0.77 17.60

Is BIOA or OGN more profitable?

Organon & Co. has a net margin of 3.41% compared to BioAge Labs' net margin of -871.75%. Organon & Co.'s return on equity of 92.94% beat BioAge Labs' return on equity. Company Net Margins Return on Equity Return on Assets BioAge Labs -871.75% -29.40% -27.26% Organon & Co. 3.41% 92.94% 6.04%

Does the media favor BIOA or OGN?

In the previous week, BioAge Labs and BioAge Labs both had 12 articles in the media. Organon & Co.'s average media sentiment score of 0.59 beat BioAge Labs' score of 0.35 indicating that Organon & Co. is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAge Labs 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Organon & Co. 5 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer BIOA or NAMS?

In the previous week, BioAge Labs had 2 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 12 mentions for BioAge Labs and 10 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.61 beat BioAge Labs' score of 0.35 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAge Labs 3 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral NewAmsterdam Pharma 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

BioAge Labs (BIOA) Competitors

$10.08 +1.04 (+11.48%)

As of 10:52 AM Eastern

Compare

BIOA vs. DNLI, RLAY, ADPT, OGN, and NAMS

Should you buy BioAge Labs stock or one of its competitors? MarketBeat compares BioAge Labs with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioAge Labs include Denali Therapeutics (DNLI), Relay Therapeutics (RLAY), Adaptive Biotechnologies (ADPT), Organon & Co. (OGN), and NewAmsterdam Pharma (NAMS).

How does BioAge Labs compare to Denali Therapeutics?

BioAge Labs (NASDAQ:BIOA) and Denali Therapeutics (NASDAQ:DNLI) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability, analyst recommendations and media sentiment.

92.9% of Denali Therapeutics shares are held by institutional investors. 17.6% of BioAge Labs shares are held by company insiders. Comparatively, 9.7% of Denali Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

BioAge Labs has higher earnings, but lower revenue than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$8.99M	47.42	-$80.61M	-$2.40	N/A
Denali Therapeutics	$330.53M	11.13	-$512.54M	-$2.88	N/A

In the previous week, BioAge Labs had 6 more articles in the media than Denali Therapeutics. MarketBeat recorded 12 mentions for BioAge Labs and 6 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.01 beat BioAge Labs' score of 0.35 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAge Labs	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Denali Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioAge Labs has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market.

Denali Therapeutics has a net margin of 0.00% compared to BioAge Labs' net margin of -871.75%. BioAge Labs' return on equity of -29.40% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-871.75%	-29.40%	-27.26%
Denali Therapeutics	N/A	-52.20%	-43.86%

BioAge Labs currently has a consensus price target of $36.57, suggesting a potential upside of 281.35%. Denali Therapeutics has a consensus price target of $35.17, suggesting a potential upside of 51.74%. Given BioAge Labs' higher probable upside, analysts clearly believe BioAge Labs is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

BioAge Labs beats Denali Therapeutics on 9 of the 16 factors compared between the two stocks.

How does BioAge Labs compare to Relay Therapeutics?

Relay Therapeutics (NASDAQ:RLAY) and BioAge Labs (NASDAQ:BIOA) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

97.0% of Relay Therapeutics shares are owned by institutional investors. 5.0% of Relay Therapeutics shares are owned by insiders. Comparatively, 17.6% of BioAge Labs shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Relay Therapeutics has a net margin of 0.00% compared to BioAge Labs' net margin of -871.75%. BioAge Labs' return on equity of -29.40% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relay Therapeutics	N/A	-43.94%	-40.11%
BioAge Labs	-871.75%	-29.40%	-27.26%

Relay Therapeutics currently has a consensus price target of $24.92, indicating a potential upside of 33.39%. BioAge Labs has a consensus price target of $36.57, indicating a potential upside of 281.35%. Given BioAge Labs' higher probable upside, analysts clearly believe BioAge Labs is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relay Therapeutics	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.86
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Relay Therapeutics had 4 more articles in the media than BioAge Labs. MarketBeat recorded 16 mentions for Relay Therapeutics and 12 mentions for BioAge Labs. Relay Therapeutics' average media sentiment score of 0.79 beat BioAge Labs' score of 0.35 indicating that Relay Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Relay Therapeutics	10 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
BioAge Labs	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Relay Therapeutics has a beta of 1.67, suggesting that its stock price is 67% more volatile than the broader market. Comparatively, BioAge Labs has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market.

BioAge Labs has lower revenue, but higher earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relay Therapeutics	$10.68M	335.20	-$276.48M	-$1.57	N/A
BioAge Labs	$8.99M	47.42	-$80.61M	-$2.40	N/A

Summary

Relay Therapeutics beats BioAge Labs on 11 of the 17 factors compared between the two stocks.

How does BioAge Labs compare to Adaptive Biotechnologies?

Adaptive Biotechnologies (NASDAQ:ADPT) and BioAge Labs (NASDAQ:BIOA) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

In the previous week, Adaptive Biotechnologies had 19 more articles in the media than BioAge Labs. MarketBeat recorded 31 mentions for Adaptive Biotechnologies and 12 mentions for BioAge Labs. Adaptive Biotechnologies' average media sentiment score of 0.50 beat BioAge Labs' score of 0.35 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	9 Very Positive mention(s)	7 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
BioAge Labs	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Adaptive Biotechnologies has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market. Comparatively, BioAge Labs has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market.

Adaptive Biotechnologies has higher revenue and earnings than BioAge Labs. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$276.98M	13.23	-$59.50M	-$0.41	N/A
BioAge Labs	$8.99M	47.42	-$80.61M	-$2.40	N/A

99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 5.7% of Adaptive Biotechnologies shares are owned by company insiders. Comparatively, 17.6% of BioAge Labs shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Adaptive Biotechnologies presently has a consensus price target of $23.33, indicating a potential upside of 1.89%. BioAge Labs has a consensus price target of $36.57, indicating a potential upside of 281.35%. Given BioAge Labs' stronger consensus rating and higher probable upside, analysts clearly believe BioAge Labs is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Adaptive Biotechnologies has a net margin of -20.73% compared to BioAge Labs' net margin of -871.75%. BioAge Labs' return on equity of -29.40% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%
BioAge Labs	-871.75%	-29.40%	-27.26%

Summary

Adaptive Biotechnologies beats BioAge Labs on 9 of the 16 factors compared between the two stocks.

How does BioAge Labs compare to Organon & Co.?

BioAge Labs (NASDAQ:BIOA) and Organon & Co. (NYSE:OGN) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk and analyst recommendations.

Organon & Co. has higher revenue and earnings than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$8.99M	47.42	-$80.61M	-$2.40	N/A
Organon & Co.	$6.13B	0.58	$187M	$0.77	17.60

Organon & Co. has a net margin of 3.41% compared to BioAge Labs' net margin of -871.75%. Organon & Co.'s return on equity of 92.94% beat BioAge Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-871.75%	-29.40%	-27.26%
Organon & Co.	3.41%	92.94%	6.04%

BioAge Labs has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.54, meaning that its stock price is 54% more volatile than the broader market.

In the previous week, BioAge Labs and BioAge Labs both had 12 articles in the media. Organon & Co.'s average media sentiment score of 0.59 beat BioAge Labs' score of 0.35 indicating that Organon & Co. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAge Labs	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Organon & Co.	5 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioAge Labs currently has a consensus price target of $36.57, suggesting a potential upside of 281.35%. Organon & Co. has a consensus price target of $11.40, suggesting a potential downside of 15.90%. Given BioAge Labs' stronger consensus rating and higher probable upside, analysts clearly believe BioAge Labs is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

77.4% of Organon & Co. shares are held by institutional investors. 17.6% of BioAge Labs shares are held by company insiders. Comparatively, 1.6% of Organon & Co. shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Organon & Co. beats BioAge Labs on 10 of the 15 factors compared between the two stocks.

How does BioAge Labs compare to NewAmsterdam Pharma?

BioAge Labs (NASDAQ:BIOA) and NewAmsterdam Pharma (NASDAQ:NAMS) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

BioAge Labs has higher earnings, but lower revenue than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$8.99M	47.42	-$80.61M	-$2.40	N/A
NewAmsterdam Pharma	$22.50M	143.70	-$203.82M	-$1.79	N/A

89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 17.6% of BioAge Labs shares are owned by insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

BioAge Labs has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market.

BioAge Labs has a net margin of -871.75% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat BioAge Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-871.75%	-29.40%	-27.26%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

In the previous week, BioAge Labs had 2 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 12 mentions for BioAge Labs and 10 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.61 beat BioAge Labs' score of 0.35 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAge Labs	3 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
NewAmsterdam Pharma	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioAge Labs currently has a consensus price target of $36.57, indicating a potential upside of 281.35%. NewAmsterdam Pharma has a consensus price target of $49.42, indicating a potential upside of 78.66%. Given BioAge Labs' higher probable upside, research analysts clearly believe BioAge Labs is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

Summary

NewAmsterdam Pharma beats BioAge Labs on 10 of the 17 factors compared between the two stocks.

Get BioAge Labs News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BIOA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BIOA vs. The Competition

Export

Metric	BioAge Labs	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$432.05M	$11.49B	$6.81B	$12.55B
Dividend Yield	N/A	2.72%	2.59%	10.03%
P/E Ratio	-4.05	796.38	282.12	24.83
Price / Sales	47.42	749.10	573.08	78.59
Price / Cash	N/A	14.82	28.60	46.71
Price / Book	1.26	10.32	11.02	6.15
Net Income	-$80.61M	$2.81B	$3.49B	$347.61M
7 Day Performance	-54.07%	2.14%	0.47%	1.17%
1 Month Performance	-61.79%	-1.98%	-4.24%	-3.46%
1 Year Performance	132.77%	157.82%	62.63%	19.43%

BioAge Labs Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BIOA BioAge Labs	3.1718 of 5 stars	$10.08 +11.5%	$36.57 +262.9%	+119.4%	$437.48M	$8.99M	N/A	N/A	News Coverage Analyst Forecast Short Interest Decrease Gap Up
DNLI Denali Therapeutics	3.0298 of 5 stars	$23.85 +3.2%	$35.17 +47.5%	+71.3%	$3.79B	$330.53M	N/A	430	Positive News Upcoming Earnings
RLAY Relay Therapeutics	3.0108 of 5 stars	$18.83 +2.1%	$24.92 +32.4%	+460.4%	$3.61B	$15.35M	N/A	330	News Coverage Upcoming Earnings
ADPT Adaptive Biotechnologies	1.5928 of 5 stars	$22.31 +0.2%	$20.83 -6.6%	+118.5%	$3.57B	$276.98M	N/A	790	Earnings Report
OGN Organon & Co.	2.0656 of 5 stars	$13.54 +0.1%	$11.40 -15.8%	+38.9%	$3.55B	$6.22B	14.55	10,000	Upcoming Earnings Dividend Announcement

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BIOA) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioAge Labs (BIOA) Competitors

BIOA vs. DNLI, RLAY, ADPT, OGN, and NAMS

How does BioAge Labs compare to Denali Therapeutics?

Summary

How does BioAge Labs compare to Relay Therapeutics?

Summary

How does BioAge Labs compare to Adaptive Biotechnologies?

Summary

How does BioAge Labs compare to Organon & Co.?

Summary

How does BioAge Labs compare to NewAmsterdam Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIOA vs. The Competition

BioAge Labs Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioAge Labs (BIOA) Competitors

BIOA vs. DNLI, RLAY, ADPT, OGN, and NAMS

How does BioAge Labs compare to Denali Therapeutics?

Do institutionals and insiders hold more shares of BIOA or DNLI?

Which has preferable valuation and earnings, BIOA or DNLI?

Does the media favor BIOA or DNLI?

Which has more risk & volatility, BIOA or DNLI?

Is BIOA or DNLI more profitable?

Do analysts recommend BIOA or DNLI?

Summary

How does BioAge Labs compare to Relay Therapeutics?

Do institutionals and insiders believe in RLAY or BIOA?

Is RLAY or BIOA more profitable?

Do analysts recommend RLAY or BIOA?

Does the media refer more to RLAY or BIOA?

Which has more risk & volatility, RLAY or BIOA?

Which has preferable earnings & valuation, RLAY or BIOA?

Summary

How does BioAge Labs compare to Adaptive Biotechnologies?

Does the media refer more to ADPT or BIOA?

Which has more risk and volatility, ADPT or BIOA?

Which has better valuation & earnings, ADPT or BIOA?

Do insiders and institutionals believe in ADPT or BIOA?

Do analysts rate ADPT or BIOA?

Is ADPT or BIOA more profitable?

Summary

How does BioAge Labs compare to Organon & Co.?

Which has stronger valuation & earnings, BIOA or OGN?

Is BIOA or OGN more profitable?

Which has more risk & volatility, BIOA or OGN?

Does the media favor BIOA or OGN?

Do analysts rate BIOA or OGN?

Do institutionals and insiders hold more shares of BIOA or OGN?

Summary

How does BioAge Labs compare to NewAmsterdam Pharma?

Which has stronger earnings & valuation, BIOA or NAMS?

Do institutionals & insiders believe in BIOA or NAMS?

Which has more volatility and risk, BIOA or NAMS?

Is BIOA or NAMS more profitable?

Does the media prefer BIOA or NAMS?

Do analysts recommend BIOA or NAMS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIOA vs. The Competition

BioAge Labs Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools